Vaishali Pharma Limited (VAISHALI) - Total Assets
Based on the latest financial reports, Vaishali Pharma Limited (VAISHALI) holds total assets worth Rs1.23 Billion INR (≈ $13.34 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vaishali Pharma Limited - Total Assets Trend (2013–2026)
This chart illustrates how Vaishali Pharma Limited's total assets have evolved over time, based on quarterly financial data. Also see Vaishali Pharma Limited market cap and net worth for the company's overall valuation and market capitalisation.
Vaishali Pharma Limited - Asset Composition Analysis
Current Asset Composition (March 2026)
Vaishali Pharma Limited's total assets of Rs1.23 Billion consist of 91.6% current assets and 8.5% non-current assets. Review Vaishali Pharma Limited total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.2% |
| Accounts Receivable | Rs507.73 Million | 41.2% |
| Inventory | Rs34.01 Million | 2.8% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs7.86 Million | 0.6% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2013–2026)
This chart illustrates how Vaishali Pharma Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Vaishali Pharma Limited (VAISHALI) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaishali Pharma Limited's current assets represent 91.6% of total assets in 2026, a decrease from 98.0% in 2013.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2026, down from 3.7% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 41.2% of total assets.
Vaishali Pharma Limited Competitors by Total Assets
Key competitors of Vaishali Pharma Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Vaishali Pharma Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.34 | 2.61 | 1.37 |
| Quick Ratio | 2.27 | 2.49 | 1.36 |
| Cash Ratio | 0.00 | 0.05 | 0.00 |
| Working Capital | Rs646.64 Million | Rs644.31 Million | Rs220.33 Million |
Vaishali Pharma Limited - Advanced Valuation Insights
This section examines the relationship between Vaishali Pharma Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.54 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 12.3% |
| Total Assets | Rs1.23 Billion |
| Market Capitalization | $12.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vaishali Pharma Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Vaishali Pharma Limited's assets grew by 12.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Vaishali Pharma Limited (2013–2026)
The table below shows the annual total assets of Vaishali Pharma Limited from 2013 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs1.23 Billion ≈ $13.34 Million |
+12.33% |
| 2025-03-31 | Rs1.10 Billion ≈ $11.88 Million |
+37.38% |
| 2024-03-31 | Rs799.56 Million ≈ $8.65 Million |
+1.33% |
| 2023-03-31 | Rs789.07 Million ≈ $8.53 Million |
-3.33% |
| 2022-03-31 | Rs816.24 Million ≈ $8.83 Million |
-5.22% |
| 2021-03-31 | Rs861.23 Million ≈ $9.31 Million |
+30.09% |
| 2020-03-31 | Rs662.04 Million ≈ $7.16 Million |
-3.70% |
| 2019-03-31 | Rs687.51 Million ≈ $7.44 Million |
+6.88% |
| 2018-03-31 | Rs643.23 Million ≈ $6.96 Million |
+44.07% |
| 2017-03-31 | Rs446.49 Million ≈ $4.83 Million |
-10.29% |
| 2016-03-31 | Rs497.73 Million ≈ $5.38 Million |
+8.69% |
| 2015-03-31 | Rs457.95 Million ≈ $4.95 Million |
-14.29% |
| 2014-03-31 | Rs534.30 Million ≈ $5.78 Million |
+9.98% |
| 2013-03-31 | Rs485.82 Million ≈ $5.25 Million |
-- |
About Vaishali Pharma Limited
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-vir… Read more